Celadon Pharmaceuticals PLC Notice of AGM (4321N)
May 31 2022 - 8:30AM
UK Regulatory
TIDMCEL
RNS Number : 4321N
Celadon Pharmaceuticals PLC
31 May 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Publication of Annual Report and Notice of Annual General
Meeting
Celadon Pharmaceuticals Plc, a leading UK based pharmaceutical
company focused on the development and supply of natural
cannabis-based medicines, announces that copies of the 2021 Annual
Report and Accounts, together with its Notice of 2022 Annual
General Meeting ("AGM"), were posted to shareholders today and are
available for viewing on the Company's website
www.celadonpharma.com .
The Company will be holding its AGM at 4.00pm on Monday 27 June
2022 at the Edgbaston Park Hotel and Conference Centre, 53
Edgbaston Park Road, Birmingham, B15 2RS.
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Andrew Potts / Patrick Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0)20 7250 1446
/ celadon@powerscourt-group.com
Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and supply of
natural cannabis-based medicines. Its primary focus is on improving
quality of life for chronic pain sufferers, as well as exploring
the potential of cannabis-based medicines for other conditions such
as autism. Its 100,000 sq. ft UK facility comprises a laboratory
designed to meet GMP standards, and capacity for a large indoor
hydroponic growing facility that has received a Home Office License
to legally grow high-THC medicinal cannabis for the purpose of
producing test batches of cannabis oil to support its application
to the MHRA. The Company's subsidiary, LVL, owns a MHRA
conditionally-approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.
For further information please visit our website
www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOABKDBNBBKDKPN
(END) Dow Jones Newswires
May 31, 2022 08:30 ET (12:30 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Apr 2024 to May 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2023 to May 2024